Clinical Trials
6
Active:1
Completed:1
Trial Phases
3 Phases
Phase 1:3
Phase 2:1
Phase 3:2
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (6 trials with phase data)• Click on a phase to view related trials
Phase 1
3 (50.0%)Phase 3
2 (33.3%)Phase 2
1 (16.7%)A Phase I/II Study of TRS005 in Combination With Cyclophosphamide, Doxorubicin, and Prednisone（T-CHP） in Previously Untreated Patients With CD20-positive DLBCL
Phase 1
Not yet recruiting
- Conditions
- Diffuse Large B-Cell Lymphoma (DLBCL)
- Interventions
- First Posted Date
- 2025-06-25
- Last Posted Date
- 2025-06-25
- Lead Sponsor
- Zhejiang Teruisi Pharmaceutical Inc.
- Target Recruit Count
- 66
- Registration Number
- NCT07035379
A Phase 2 Study of TRS005 in Patients With CD20-positive R/R DLBCL.
Phase 2
Not yet recruiting
- Conditions
- CD20-positive Diffuse Large B-Cell Lymphoma
- Interventions
- First Posted Date
- 2025-03-20
- Last Posted Date
- 2025-06-11
- Lead Sponsor
- Zhejiang Teruisi Pharmaceutical Inc.
- Target Recruit Count
- 139
- Registration Number
- NCT06886139
- Locations
- 🇨🇳
Chinese Academy of Medical Sciences, Cancer Hospital, Beijing, Beijing, China
A Phase 1 Study of TRS005 in Patients With R/R CD20-positive B-NHL.
Phase 1
Active, not recruiting
- Conditions
- CD20-positive B-cell Non-Hodgkin Lymphoma
- Interventions
- Drug: Recombinant CD20 monoclonal antibody-MMAE conjugte for injection
- First Posted Date
- 2022-05-27
- Last Posted Date
- 2025-06-25
- Lead Sponsor
- Zhejiang Teruisi Pharmaceutical Inc.
- Target Recruit Count
- 147
- Registration Number
- NCT05395533
- Locations
- 🇨🇳
Chinese Academy of Medical Sciences, Cancer Hospital, Beijing, Beijing, China
🇨🇳Sun Yat-sen University Cancer Center (SYSUCC), Guangzhou, Guangdong, China
🇨🇳Henan Cancer Hospital (Affiliated Cancer Hospital of Zhengzhou University), Zhengzhou, Henan, China
A Study Assessing the Interchangeability Between TRS003 and Bevacizumab® For CRC
Phase 3
- Conditions
- Metastatic Colorectal Cancer (CRC)
- Interventions
- Biological: TRS003Biological: China-approved BevacizumabDrug: mFOLFOX6
- First Posted Date
- 2022-05-18
- Last Posted Date
- 2022-05-18
- Lead Sponsor
- Zhejiang Teruisi Pharmaceutical Inc.
- Target Recruit Count
- 126
- Registration Number
- NCT05378867
A Study to Compare the Similarity in Efficacy and Safety Between TRS003 and China-approved Bevacizumab® in NSCLC
Phase 3
- Conditions
- Advanced Non-squamous Non-small-cell Lung Cancer
- Interventions
- First Posted Date
- 2020-06-04
- Last Posted Date
- 2020-08-31
- Lead Sponsor
- Zhejiang Teruisi Pharmaceutical Inc.
- Target Recruit Count
- 608
- Registration Number
- NCT04416035
- Locations
- 🇨🇳
Anhui Provincial Center Hospital, Hefei, Anhui, China
🇨🇳Chinese Academy of Medical Sciences, Cancer Hospital, Beijing, Beijing, China
🇨🇳Beijing Hospital, Beijing, Beijing, China
- Prev
- 1
- 2
- Next
News
No news found